| Protein Name |
Cyclic AMP-dependent transcription factor ATF-2 |
| Gene |
ATF2 |
| UniProt |
P15336 |
| Molecular Weight |
70 kDa |
| Structure |
bZIP transcription factor domain, transactivation domain |
| Subcellular Localization |
Nucleus |
| Protein Family |
ATF/CREB family |
ATF2 (Activating Transcription Factor 2) is a member of the ATF/CREB (cAMP Response Element Binding) family of transcription factors. As a stress-responsive transcription factor, ATF2 plays critical roles in gene expression regulation in response to cellular stress, inflammatory signals, and DNA damage. In the nervous system, ATF2 regulates genes involved in neuronal survival, synaptic plasticity, and the cellular response to neurodegeneration. UniProt ID: P15336.
ATF2 is a 505-amino acid protein that functions as a transcriptional activator in response to various stress signals. It operates as a homodimer or heterodimer with other bZIP family transcription factors, particularly c-Jun, to regulate gene expression through binding to CRE (cAMP Response Element) and AP-1 sites in gene promoters 1.
¶ Domain Architecture
ATF2 contains several functionally distinct domains:
¶ N-terminal Regulatory Domain (residues 1-200)
- Contains multiple phosphorylation sites
- Thr69 and Thr71: Primary phosphorylation sites for JNK and p38
- Ser90: PKA phosphorylation site
- Ser121: DNA-dependent protein kinase (DNA-PK) site
- Regulatory functions through post-translational modification
¶ bZIP Domain (residues 201-260)
- Basic region (positions 235-255): DNA-binding domain that contacts the CRE sequence (TGACGTCA)
- Leucine zipper (positions 260-350): Dimerization interface for homodimer and heterodimer formation
- Enables formation of ATF2/Jun heterodimers with distinct DNA binding specificity
¶ Transcriptional Activation Domain (residues 350-505)
- C-terminal region responsible for transcriptional activation
- Functions in concert with coactivators (CBP/p300)
- Activity regulated by phosphorylation
- Phospho-dependent activation: Phosphorylation of N-terminal residues induces conformational changes
- Dimerization flexibility: Can form homodimers, heterodimers with Jun, and other bZIP proteins
- Nuclear localization: Contains nuclear localization signals (NLS) in the bZIP domain
ATF2 is primarily activated by stress-activated protein kinase (SAPK) pathways:
- c-Jun N-terminal kinases (JNK1/2/3) phosphorylate ATF2 at Thr69 and Thr71
- JNK activation occurs in response to:
- Cytotoxic stress (UV, oxidative stress)
- Excitotoxicity
- Neuroinflammation
- Protein aggregate stress
- p38 α/β isoforms phosphorylate ATF2
- Links inflammatory signals to gene expression
- Important for cytokine and chemokine expression
ATF2 regulates genes involved in:
- c-Jun: Component of AP-1 complex
- Mdm2: E3 ubiquitin ligase
- Bcl-2 family: Pro-apoptotic and anti-apoptotic genes
- IL-6, IL-8: Pro-inflammatory cytokines
- COX-2: Cyclooxygenase-2, inflammation mediator
- TNF-α: Tumor necrosis factor alpha
- p53: Tumor suppressor and DNA damage response
- GADD45: Growth arrest and DNA damage-inducible gene
- Synaptic proteins: Postsynaptic density components
- Neurotrophic factors: BDNF, NGF
ATF2 activation occurs in response to amyloid-β (Aβ) exposure:
- Aβ-induced oxidative stress activates JNK/p38 pathways
- ATF2 phosphorylation increases in AD brain 2
- Contributes to inflammatory gene expression
- ATF2 regulates pro-inflammatory cytokine expression
- Chronic ATF2 activation perpetuates neuroinflammation
- Creates vicious cycle of toxicity and inflammation
- ATF2 can promote pro-apoptotic gene expression
- In complex with c-Jun, regulates Bim, FasL
- Contributes to neuronal loss in AD
- ATF2 activated in response to:
- 6-OHDA toxicity
- MPTP exposure
- Oxidative stress
- Mitochondrial dysfunction 3
- ATF2 responds to α-synuclein aggregation stress
- May regulate genes involved in protein clearance
- Therapeutic modulation being explored
- JNK/ATF2 pathway in microglial activation
- Regulates cytokine expression in PD brain
- Target for anti-inflammatory therapies
¶ Stroke and Ischemia
- ATF2 rapidly activated following cerebral ischemia
- Contributes to both adaptive and maladaptive responses
- Regulates genes involved in:
- Excitotoxicity
- Oxidative stress
- Inflammation
- Apoptosis 4
- Sublethal ATF2 activation can induce neuroprotection
- Potential therapeutic window for stroke treatment
- ATF2 activated in response to:
- Mutant SOD1 toxicity
- Excitotoxicity (glutamate)
- Oxidative stress
- ER stress 5
- Regulates inflammatory response in microglia
- Contributes to non-cell autonomous toxicity
- ATF2 activated in response to mutant huntingtin
- May regulate stress response genes
- Can be protective or detrimental depending on context 6
- SP600125: JNK inhibitor reduces ATF2 phosphorylation
- JNK-IN-8: Selective JNK inhibitor
- D-JNKI1: Cell-penetrating JNK inhibitor
- SB203580: p38 MAPK inhibitor
- BIRB796: Pan-p38 inhibitor
- ATF2-specific siRNA reduces neuronal death in models
- Challenge: delivery to neurons in vivo
- dCas9-KRAB for ATF2 repression
- Potential for allele-specific targeting
- ATF2 modulators must balance protective and harmful effects
- Timing and context matter significantly
- Combination approaches may be necessary
- Reducing ATF2-mediated inflammation
- Protecting neurons from chronic activation
¶ Current Understanding
- ATF2 is a stress-responsive transcription factor
- Activation contributes to both protective and pathological responses
- Context-dependent function complicates therapeutic targeting
- Neuron-specific ATF2 functions
- Cell type-specific isoforms or partners
- Optimal targeting strategies
- No ATF2-targeted therapies in clinical trials
- JNK/p38 inhibitors in development for other indications
- Potential for repurposing
-
ATF2 structure and transcriptional regulation (2002). Oncogene.
-
JNK signaling in neurodegeneration (2002). Nature Reviews Neuroscience.
-
Stress-activated protein kinases in Parkinson's disease (2002). Trends in Neurosciences.
-
JNK pathway in cerebral ischemia (2004). Neurobiology of Disease.
-
Stress kinases in ALS (2009). Molecular Neurodegeneration.
-
ATF2 in Huntington's disease (2011). Human Molecular Genetics.
The study of Atf2 Protein — Activating Transcription Factor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hai T, Curran KA. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA. 2003;100(9):5516-5521. PMID:12716933
[2] Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239-252. PMID:11862281
[3] Xu P, Davis RJ. c-Jun N-terminal kinases in Parkinson's disease. Nat Rev Neurosci. 2002;3(5):351-357. PMID:12450780
[4] Irving EA, et al. The role of JNK activation in cerebral ischemia. Neurobiol Dis. 2004;17(2):187-197. PMID:15276739
[5] Ryu H, et al. JNK pathway in neurodegenerative diseases. Mol Neurodegener. 2009;4:25. PMID:19918255
[6] Zhang Y, et al. ATF2 regulates neuronal death in Huntington's disease. Hum Mol Genet. 2011;20(14):2735-2745. PMID:21796149